Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...
On location

Evaluating Two New Options for Hereditary Hemorrhagic Telangiectasia

At EHA2021 Virtual, researchers shared safety and efficacy findings of two agents for the treatment of the rare disease hereditary hemorrhagic telangiectasia (HHT): pazopanib...
On location

Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma

In the GELTAMO ICML-2015 study, treatment with frontline ibrutinib in combination with rituximab demonstrated high rates of efficacy in patients with indolent mantle cell...
On location

Evaluating a Response-Adapted Rituximab Approach for Patients With Follicular Lymphoma

In patients with follicular lymphoma (FL), standard rituximab maintenance produced better rates of progression-free survival (PFS) than an experimental response-adopted approach, according to results...
On location

Does Khorana Score Accurately Predict VTE in Patients With Uterine and Ovarian Cancer?

At the 2021 ASCO Annual Meeting, researchers shared results from two studies examining the Khorana score for predicting venous thromboembolism (VTE) in patients with...
On location

PDE9 Inhibitor Shows Promise as Monotherapy and With Hydroxyurea in Sickle Cell Disease

Data from two new studies indicated that daily dosing of the oral phosphodiesterase type 9 (PDE9) inhibitor IMR-687, at doses up to 200 mg,...
On location

Letermovir Prevents Cytomegalovirus Infection and Improves Survival Post-Transplant

Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell...
On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen proved safe...
On location

Deep and Durable Responses Seen With CAR T-Cell Therapy for Pretreated Myeloma

In preliminary efficacy results, treatment with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) led to early, deep, and durable responses in patients with...
On location

Direct Oral Anticoagulants Versus LMWH in Preventing Recurrent VTE in Cancer

At the 2021 ASCO Annual Meeting, two posters reported results from the CANVAS trial, which described the risk-benefit profiles of direct oral anticoagulants (DOACs)...
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title